Tumor protein 53 (TP53) is critical to cell cycle control and is the most common mutational target in germinal center lymphomas. However, these mutations occur infrequently at diagnosis ( G substitution at nucleotide 309 of intron one and leads to higher MDM2 mRNA and protein expression with lower apoptotic response. Significantly, homozygosity for the G allele correlates with earlier onset of de novo diffuse large B-cell lymphoma (DLBCL) in females7 Its role in CLL is less clear as two recent studies provide contrasting results.8,9 TP53 Arg72Pro is a non-synonymous SNP involving G>C substitution at nucleotide 466 of exon 4 in TP53 which creates a TP53 protein with reduced potential to induce apoptosis or suppress cell transformation.10 These SNPs are also associated with poor prognosis or increased cancer risk in certain solid malignancies.11,12 We investigated the relationship of the allelic combinations for both SNPs with the following clinical variables in cases of FL: age, gender, stage at diagnosis, response to first line therapy, best response to therapy, progression-free survival, relapse-free survival, overall survival and time to transformation (Details of each variable are available in the Online Supplementary Table S1). A real-time polymerase chain reaction Allelic Discrimination multiplexed endpoint assay protocol using the ABI PRISM™ 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA) was used to determine the SNP alleles present in DNA of 226 patient samples from bone marrow (n=207), peripheral blood (n=14) or lymph nodes (n=5). (Oligonucleotide sequences used are available on request.) Samples were obtained from the tissue archive at St Bartholomew’s Hospital under Institutional Ethical Approval obtained from the Local Ethics Committee. Reactions were performed in duplicate including homozygous and heterozygous controls for each SNP genotype and a no DNA template control. Positive controls were confirmed by direct sequencing. In this patient cohort, allelic frequencies were similar to previously published results at 44%, 43%, 13% for MDM2 SNP 309 TT, TG, GG and at 46%, 46%, 8% for TP53 Arg72Pro GG, GC, CC respectively (Online Supplementary Table S2) and both polymorphisms satisfied the Hardy-Weinberg equilibrium. Median age at diagnosis was 46 years, which is younger than that previously described for FL, and reflects our status as a tertiary referral center for patients with FL. There was no difference in the median age at diagnosis for each of the 3 allelic combinations of MDM2 SNP 309 (both for the whole study population and for gender in contrast to findings in DLBCL7) and of TP53 Arg53Pro (Online Supplementary Table S2). Relationships between SNP alleles and clinical parameters were studied using χ2 test for stage and gender, analysis of variance (ANOVA) for age and Kruskal-Wallis test for responses to therapy. The 3 allelic combinations for each SNP were informally assessed as well as formally assessing two groups of patient samples consisting of those homozygous for the common allele or those with at least one rare allele, enabling any dominant effects of the MDM2 SNP 309 G or TP53 Arg72Pro C alleles, as described in other malignancies, to be assessed in FL. As MDM2 SNP 309 can lead to earlier onset or more advanced disease6 and TP53 negatively regulates MDM2 expression, we assessed MDM2 SNP 309 alleles in isolation or in combination with TP53 Arg72Pro alleles against these clinical parameters; there was no evidence of any association (illustrated in Table 1 for gender, stage and responses to therapy; p≥0.13). Kaplan-Meier plots and log rank test statistics demonstrated no evidence for associa-ion oft MDM2 SNP 309 or TP53 Arg72Pro allelic variants alone, or in combination, with overall survival (Figure 1A), progression free survival, relapse free survival or time to transformation (Figure 1B) (p≥0.17). Table 1. Assessment of MDM2 SNP 309 and TP53 Arg72Pro against clinical parameters Figure 1. Kaplan-Meier plots and log rank test statistics for overall survival (A) and time to transformation (B) by MDM2 SNP 309 and TP53 Arg72Pro alleles. Illustrated are results for four groups of allelic combinations of the two SNPs. The four groups Neither ... Consequently, whilst genomic lesions targeting the MDM2-TP53 axis are an important feature of FL, MDM2 SNP 309 and TP53 Arg72Pro do not predict clinical outcome. In contrast to other malignancies these polymorphisms are not significant in FL.
Read full abstract
Feb 19, 2013
Cristiani Cortez Mendes + 12
Open Access
